OncoMatch/Clinical Trials/NCT02429700

TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors

Is NCT02429700 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for ovarian sex cord stromal tumor.

Phase 3RecruitingBeihua KongNCT02429700Data as of May 2026

Treatment: Paclitaxel · Carboplatin · Bleomycin · Etoposide · Cisplatin — Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed ovarian malignant sex cord-stromal tumor patients after surgery.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Disease stage

Required: Stage IIA, IIB, IIC, IIIA, IIIB, IIIC, IVA, IVB

Prior therapy

No prior treatment (treatment-naive required)

Must have received: surgery — initial

Has undergone initial surgery (for diagnosis, staging, or cytoreduction) within the past 8 weeks.

Lab requirements

Blood counts

wbc≥4×10(9)/l, neu≥2×10(9)/l, plt≥80×10(9)/l

Kidney function

bun, cr≤ normal

Liver function

serum bilirubin≤ 1.5 times the upper limit of normal, transaminase≤ 1.5 times the upper limit of normal

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify